New hope for sarcoma patients: novel drug combo enters human trials

NCT ID NCT07359053

Recruiting now Disease control Sponsor: Shanghai 6th People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new combination of drugs for people with advanced bone or soft tissue sarcomas that have worsened after initial treatment. The combo includes a safer form of paclitaxel, standard chemotherapy, and a targeted therapy chosen based on tumor type. About 46 participants will receive the treatment to see if it shrinks tumors and to monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Paclitaxel polymer micelles, gemcitabine, lenvatinib, and anlotinib
What this could lead to: If successful, this could offer a new treatment option for people with advanced sarcomas who have run out of standard therapies.
What could go wrong: This is an early-phase, small study (46 people) with no control group, so results may not be definitive. The drug combination may cause significant side effects like fatigue, high blood pressure, or low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone sarcoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA

Contacts and locations

Locations

Shanghai Sixth Peolple'S Hospital
RECRUITING

Shanghai, CH, 200233, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.